ESR1 and breast carcinoma: The current standards of care for ERα + breast cancer include the selective estrogen receptor modulator (SERM) tamoxifen or the selective estrogen receptor down regulator (SERD) fulvestrant, and a combination of additional targeted agents, such as monoclonal antibodies or cyclin-dependent kinase inhibitors (Johnston and Cheung, 2018).